{"links":{"html":"https://www.erudio.com/reports/kandlelit-001-nct05067283","json":"https://www.erudio.com/reports/kandlelit-001-nct05067283.json","markdown":"https://www.erudio.com/reports/kandlelit-001-nct05067283.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"kandlelit-001-05067283"}},"request":"https://www.erudio.com/contact?report=kandlelit-001-05067283"},"offer":{"cited_commentary_sources":18,"verified_hcp_statements":52,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":9,"optional":true,"price_per_verified_person_usd":15,"price_usd":135,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"kandlelit-001-nct05067283"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=kandlelit-001-05067283","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/kandlelit-001-nct05067283","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T12:49:48.734834Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":1},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)"},{"claim_count":6,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":6,"title":"Primary endpoint: Number of Participants Who Experience an Adverse Event (AE)"},{"claim_count":3,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":3,"title":"Primary endpoint: Number of Participants Who Discontinue Study Treatment Due to an AE"},{"claim_count":18,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":9,"title":"Secondary endpoints"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":10,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":10,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":7,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":10,"coverage":"discussed","id":"A1","source_count":4,"title":"Evidence needed before frontline NSCLC practice change"},{"claim_count":2,"coverage":"discussed","id":"A2","source_count":2,"title":"Previously treated NSCLC: response frequency versus durability"},{"claim_count":10,"coverage":"discussed","id":"A3","source_count":4,"title":"Tumor-specific enthusiasm outside NSCLC and colorectal cancer"},{"claim_count":3,"coverage":"discussed","id":"A4","source_count":1,"title":"Active-treatment access and approval-based reassurance"},{"claim_count":4,"coverage":"discussed","id":"A5","source_count":2,"title":"Combination-era expectations and wider anti-KRAS G12C competition"}],"counts":{"cited_sources":18,"claims_by_expression_type":{"comparison":2,"interpretation":20,"opinion":7,"primary_context":3,"restatement":11,"uncertainty":3,"unspecified":6},"claims_by_kind":{"source_observation":52},"clinician_statements":11,"evidence_units":28,"findings":6,"organisational_accounts":2,"people_cited":12,"people_identity_verified":9,"people_total":12,"screened_sources":59,"verified_claims":52},"findings_index":[{"id":"F1","structure":{"claims":13,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":10},"has_counterview":false,"limitations":3,"links":{"context":2,"support":13},"ma_question":true,"named_voices":3,"passages":7,"sources":5,"sources_by_kind":{"commentary":3,"media":2}},"title":"Frontline NSCLC enthusiasm remains conditional on randomized evidence and hepatic safety"},{"id":"F2","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":0,"questions":3,"restated":7,"views":1},"has_counterview":false,"limitations":3,"links":{"context":1,"support":15},"ma_question":true,"named_voices":5,"passages":6,"sources":6,"sources_by_kind":{"commentary":6}},"title":"CRC doublet enthusiasm does not extend unqualified to the chemotherapy triplet"},{"id":"F3","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":6},"ma_question":true,"named_voices":0,"passages":2,"sources":1,"sources_by_kind":{"media":1}},"title":"Participation messaging pairs active-treatment access with an unverified approval premise"},{"id":"F4","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":4},"has_counterview":false,"limitations":2,"links":{"context":2,"support":7},"ma_question":true,"named_voices":1,"passages":5,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"Previously treated NSCLC: modest response frequency and durability are separate judgments"},{"id":"F5","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":5,"views":9},"has_counterview":false,"limitations":3,"links":{"context":8,"support":14},"ma_question":true,"named_voices":2,"passages":4,"sources":4,"sources_by_kind":{"commentary":2,"media":2}},"title":"The presenter expresses emphatic, tumor-specific enthusiasm outside NSCLC and CRC"},{"id":"F6","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":3},"has_counterview":false,"limitations":3,"links":{"context":1,"support":4},"ma_question":true,"named_voices":3,"passages":4,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Combination-era optimism sits alongside speculative competitive positioning"}],"medical_affairs_question":"Which mature, randomized and regimen-specific efficacy and safety findings would resolve the expressed uncertainty without turning exploratory signals into treatment recommendations?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Frontline NSCLC: enthusiasm with an explicit evidence threshold"},{"id":"section-2","level":2,"title":"CRC: enthusiasm for the doublet, questions about added chemotherapy"},{"id":"section-3","level":2,"title":"Participation information: active treatment is not an approval or benefit guarantee"},{"id":"section-4","level":2,"title":"Previously treated NSCLC: modest frequency can coexist with durable responses"},{"id":"section-5","level":2,"title":"Other solid tumors: emphatic but narrowly scoped presenter enthusiasm"},{"id":"section-6","level":2,"title":"Combination-era expectations and wider KRAS G12C competition"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, parallel, phase1","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T2","label":"Primary endpoint: Number of Participants Who Experience an Adverse Event (AE)"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T3","label":"Primary endpoint: Number of Participants Who Discontinue Study Treatment Due to an AE"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F2","shared_claims":4},{"id":"F4","shared_claims":3},{"id":"F5","shared_claims":6}],"id":"T4","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":7},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":1}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":4},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":3}],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":2}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T12:49:48.734834Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T13:01:28Z","record_hash":"a522ba3a2c908b45dd5e42037d34c310c8fa1174d3203612cfed30d26cee28fe","release_hash":"4a6b74948b1393307240e451d8da1986a38cc35156807905f0484bf30c22e078","report_id":"erudio-nct05067283","run_id":"e1a59800-e95d-403c-924a-b87b0eea6d8a","schema_version":"5.0","slug":"kandlelit-001-05067283","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"KANDLELIT-001 asks whether calderasib, alone or in combinations, can provide tolerable treatment and antitumor activity in advanced KRAS G12C-mutated cancers. Commentary comes from X and LinkedIn posts and YouTube interviews; clinical roles are not established for every contributor. Discussion turns on what randomized evidence and hepatic safety would support frontline calderasib–pembrolizumab, whether chemotherapy adds value in colorectal cancer combinations, and how response frequency relates to durability with calderasib monotherapy in previously treated NSCLC.","meta_description":"59 sources screened · 52 verified statements (11 from clinicians verified by NPI or staff page) from 18 sources · 6 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-6e3e3bc5611db417991f"],"id":"F1","paraphrase":"An X post addresses what evidence would inform treatment decisions about first-line calderasib plus pembrolizumab in KRAS G12C-mutated NSCLC.","publication_caveats":{"reason":"Source-specific publication caveats are not specified.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-10-25","title":"Frontline NSCLC enthusiasm remains conditional on randomized evidence and hepatic safety"},{"cited_claim_ids":["claim-755c76e237810e4e5c3c","claim-83f5c1535dc54aff1108"],"id":"F2","paraphrase":"An X thread addresses what adding chemotherapy contributes to MK-1084 plus cetuximab in advanced colorectal cancer.","publication_caveats":{"reason":"Source-specific publication caveats are not specified.","status":"not_set"},"source_channel":"x_thread","source_date":"2025-05-23","title":"CRC doublet enthusiasm does not extend unqualified to the chemotherapy triplet"}]},"publication":{"approved_at":"2026-10-31T13:01:28Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":59},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","45 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","Repeated posts, institutional presentation coverage, reshares and closely matching interview versions are not independent HCP assessments.","The reported cohort results differ in population, prior treatment, biomarker group, regimen and presentation. Common analysis dates are not established, and the figures cannot support a simple cross-cohort efficacy ranking.","CRC triplet safety is reported differently: 25% grade ≥3 treatment-related adverse events in a speaker's account versus 15% grade 3+ adverse events in another speaker's. The event definitions and numerical difference remain unresolved.","No full protocol or results publication is available in the material reviewed. Regulatory information is incomplete and does not establish the trial-information video's assertion that all constituent drugs are approved.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Post and video publication dates are not necessarily presentation dates. Differences between reports do not establish a change of mind or disagreement across settings."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":2,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":10,"x_video":0,"youtube":5},"by_evidence_role":{"commentary":18},"count":18,"evidence_window":{"end":"2026-10-25","start":"2023-09-15"},"retrieval_snapshot":"2026-10-31T12:13:36.321731Z","timeline":[{"count":1,"week":"2023-W37"},{"count":3,"week":"2025-W21"},{"count":1,"week":"2025-W22"},{"count":2,"week":"2025-W42"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W46"},{"count":2,"week":"2026-W02"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W19"},{"count":2,"week":"2026-W31"},{"count":3,"week":"2026-W43"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT05067283:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05067283:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:38924388","quote_policy":"short_quote_link_out"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"openfda:4c89cedc-e48b-445c-ad05-54dbe60e4fb0:20260721","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-47eyg4sm7lvqbke5glkahofa-3m3fkkao6ls25","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-cg5bjyxf74w3vg7lo4zqwpzg-3mbvrvfcjpv2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3lqf7u2d5oz2w","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-nus2cx6cwpbqdj7j655m7bwo-3m3fmj2flgs2s","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-pwbuf4hieo24wlhs7d7fmfhl-3mhdn7ckrr22z","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-pwbuf4hieo24wlhs7d7fmfhl-3mhioza477k2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-pwbuf4hieo24wlhs7d7fmfhl-3mhnfdcb3fc2e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ulozjjf5jrge3s4yr7luulgu-3miqmjz3vus2z","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7384968454816165888","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7385223381744312320","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7385249676901462016","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1918712360807673966:261a9839-5d89-4e28-88cf-841eb4628ed8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925682033939910861:6c5a4e2c-0ce4-40fa-8615-59ddeee0079f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925718408374428075:2559b95d-0e59-42a8-8f5d-1277d5325c78","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1925864932186144975:be9837d0-5efe-43c6-b7a1-b193820fa249","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926356968655986813:828ff331-6691-41de-b47a-72a438491a4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926698248288293345:04f7f5f6-0576-473a-8575-355e440fbc32","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928426870812377376:b9b87427-0e70-4d53-a417-6e01f427973d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928463407419703631:d578e3a3-1311-4a91-b020-e3229b5c3bdf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928578798129213854:47e29539-0e9b-4e42-8fbf-93ee14e2fe37","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928935359619973328:984d477a-216c-44d6-bb0c-f30147d916b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928937483133137156:34d7bcc2-bb9b-4117-a845-172c29d632fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928942175863120236:2b431e99-94b5-43d3-9bba-32acb5b7f456","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1928983586079912118:91722554-68b7-42f6-b2d9-7f05e74e1142","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929567445796126807:66d9579a-c83f-4cf2-94bb-ccad3bd99a72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978409393134645439:94d90f42-8210-44f0-a95b-a843ba192afc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979203051207471366:6b9e9a99-6bb0-4c1d-b7a3-5beb21cf8f40","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1985452267701428300:2df2dd2b-a7a9-494b-a244-e9d687aced77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009213547880820752:c4da80d4-0c4c-4c6f-98a9-16f1854b173d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2034267075406114923:c879a4a2-6c76-4ca1-86d8-4c78a9287e10","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2034995890264670724:10e49d24-883c-4880-a9d6-ebc8d90fb798","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037055894421463365:af54e8f5-8bfa-48d9-a0d4-74124d83ba40","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037184739879108938:99cedb57-720e-4093-8905-fefbe5614b94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037184977327083850:9b4d7e07-1dc2-44d7-8e53-2bb660c176cd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037795795190292667:adeb3dd2-e796-4f1b-9eea-49d73f3ddb1f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2044799671806148920:862883b2-0655-4148-aa62-4134a1fcd489","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2044799771093700824:ad0cfa81-744c-40f5-bf34-6bbfb09e383c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053391169204232207:245d86aa-e116-4d42-8e78-88786006c7df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053832644517872128:c6be46cf-644c-409b-ac03-179282443fb6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060337757780869162:6fd7ac36-8b37-470e-b61e-131f62656abb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2070919860834504866:8d1ba00c-d660-45fe-9d94-379a173116bc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2071649027104633213:dad202e7-19b2-4c55-8b17-41f79975a795","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2082873969263124567:5b4f4062-b02d-4758-9d9c-792d6cc4cd12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103831961269674371:7f54d509-5d1b-4b55-ae06-065c6b5c7cd1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105041697919148510:b9405ea4-e102-4f7b-a45c-b1601db05846","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2112899205287297231:fbf8c798-8025-41c5-bf13-7368e580f633","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113944302778798584:1fa0ef75-3478-44b0-a046-3c53de615c99","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114044158851870917:2c54919f-cf0b-46ab-b142-ddb4c92640fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114275529130180957:c04afde9-a0b4-43df-9b95-a0443798047b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114275614949888106:4a9a08ec-a9de-46e1-a213-6a32ddc0081b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114277408723423613:0f230174-581e-4aaf-a5c3-02df2a7e4771","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114280536759783901:edb5a5a5-b5c6-447b-8c20-79cdf08d9295","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114313114283819451:9f04114b-f03d-4237-8687-af79f2d5093a","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:1JZFFH7AujQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:4-h_mHwDMnE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:9bbCmKFDpR0","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:YF6UKdloCWA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:aAoPUElR-OM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:jYJHw6cZUJQ","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":8,"linkedin_post":3,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":42,"x_video":0,"youtube":6},"by_evidence_role":{"commentary":59},"count":59,"evidence_window":{"end":"2026-10-25","start":"2023-09-15"},"retrieval_snapshot":"2026-10-31T12:13:36.321731Z","timeline":[{"count":1,"week":"2023-W37"},{"count":1,"week":"2025-W18"},{"count":5,"week":"2025-W21"},{"count":8,"week":"2025-W22"},{"count":2,"week":"2025-W23"},{"count":7,"week":"2025-W42"},{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W45"},{"count":1,"week":"2025-W46"},{"count":2,"week":"2026-W02"},{"count":5,"week":"2026-W12"},{"count":4,"week":"2026-W13"},{"count":1,"week":"2026-W14"},{"count":2,"week":"2026-W16"},{"count":2,"week":"2026-W19"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W26"},{"count":1,"week":"2026-W27"},{"count":2,"week":"2026-W31"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":8,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: calderasib","status":"unmapped"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Alimta"],"label":"pemetrexed","slug":"pemetrexed"},{"brand_names":["Erbitux"],"label":"cetuximab","slug":"cetuximab"},{"brand_names":["Eloxatin"],"label":"oxaliplatin","slug":"oxaliplatin"},{"brand_names":["Vykoura","Wellcovorin"],"label":"leucovorin","slug":"leucovorin"},{"brand_names":["Adrucil","Favlyxa"],"label":"fluorouracil","slug":"fluorouracil"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Advanced solid tumors","slug":"advanced-solid-tumors"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"KANDLELIT-001","aliases":["KANDLELIT-001","A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)","A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors"],"brief_title":"A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Advanced Solid Tumors"],"display_condition":"KRAS G12C-mutant advanced solid tumors","display_interventions":[["calderasib (MK-1084)"],["calderasib (MK-1084)","pembrolizumab"],["calderasib (MK-1084)","cetuximab"]],"enrollment":{"count":830,"type":"ESTIMATED"},"interventions":[{"name":"Calderasib","synonyms":["MK-1084"],"type":"DRUG"},{"name":"Pembrolizumab","synonyms":["KEYTRUDA®","MK-3475"],"type":"BIOLOGICAL"},{"name":"carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"pemetrexed","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"cetuximab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"BIOLOGICAL"},{"name":"oxaliplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"leucovorin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"5-fluorouracil","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05067283","official_title":"A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors","overall_status":"RECRUITING","phase":["PHASE1"],"primary_completion_date":{"date":"2030-02-25","type":"ESTIMATED"},"primary_endpoints":[{"description":"A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). Number of participants who experience a DLT will be reported.","measure":"Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)","timeFrame":"Up to ~21 days"},{"description":"An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be reported.","measure":"Number of Participants Who Experience an Adverse Event (AE)","timeFrame":"Up to ~56 months"},{"description":"An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported.","measure":"Number of Participants Who Discontinue Study Treatment Due to an AE","timeFrame":"Up to ~56 months"}],"registered_date":{"date":"2021-10-05","type":"ACTUAL"},"registry_last_updated":"2026-10-07","registry_url":"https://clinicaltrials.gov/study/NCT05067283","short_name":"KANDLELIT-001","short_name_basis":"registry_acronym","sponsor":"Merck Sharp & Dohme LLC","start_date":{"date":"2021-12-17","type":"ACTUAL"},"study_design":"interventional, non randomized, parallel, phase1","study_ids":[{"id":"1084-001","type":"sponsor_study_id"},{"domain":"MSD","id":"MK-1084-001","type":"other"},{"domain":"jRCT","id":"jRCT2041220034","type":"registry"},{"domain":"EU CT","id":"2022-501563-40-00","type":"registry"},{"domain":"UTN","id":"U1111-1281-2482","type":"registry"}],"study_type":"INTERVENTIONAL"}}}